ModeX Therapeutics Inc., an OPKO Health company, announces dosing of the first participant in the phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback